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ABSTRACT: This study was undertaken to
determine whether the production of melatonin, a hor-
mone regulating sleep in relation to the light/dark cycle,
is altered in Huntington’s disease. We analyzed the cir-
cadian rhythm of melatonin in a 24-hour study of
cohorts of control, premanifest, and stage II/III Hunting-
ton’s disease subjects. The mean and acrophase mela-
tonin concentrations were significantly reduced in stage
II/III Huntington’s disease subjects compared with con-
trols. We also observed a nonsignificant trend toward
reduced mean and acrophase melatonin in premanifest
Huntington’s disease subjects. Onset of melatonin rise
was significantly more temporally spread in both pre-
manifest and stage II/III Huntington’s disease subjects
compared with controls. A nonsignificant trend also
was seen for reduced pulsatile secretion of melatonin.
Melatonin concentrations are reduced in Huntington’s
disease. Altered melatonin patterns may provide an
explanation for disrupted sleep and circadian behavior
in Huntington’s disease, and represent a biomarker for
disease state. Melatonin therapy may help the sleep
disorders seen in Huntington’s disease. VC 2014 The
Authors. Movement Disorders published by Wiley
Periodicals, Inc. on behalf of International Parkinson
and Movement Disorder Society.
Key Words: Huntington’s disease; melatonin; circa-
dian rhythm
Huntington’s disease (HD) is an autosomal dominant
neurodegenerative disorder caused by an expanded
CAG repeat in the gene encoding huntingtin.1 It is char-
acterized by progressive chorea and cognitive and psy-
chiatric disturbance. Other features include weight loss
and sleep disturbance.2,3 Disturbed sleep is reported in
80% of cases of HD, with reduced sleep efficiency and
altered architecture,3 and later increased sleep latency,
frequent nocturnal awakenings, and delayed and short-
ened rapid-eye-movement sleep.4-6 R6/2 HD mice have
progressive disruption of day–night circadian behavior,
accompanied by dysregulation of suprachiasmatic
nucleus (SCN) circadian clock genes.7 In another mouse
model, reduced rhythms in spontaneous electrical activ-
ity in SCN neurons were demonstrated.8
Melatonin is secreted by the pineal gland mainly at
night, regulating sleep and other circadian processes. The
SCN regulates melatonin synthesis via a polysynaptic
pathway in response to the light/dark cycle, important in
signaling “time of day.”9 Degeneration of the SCN in
HD could influence melatonin secretion, disrupting sleep
and circadian rhythms. One study has analyzed melatonin
profiles and found a delay in evening rise of melatonin in
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HD, which may not explain the range of HD sleep disor-
ders.10 As part of a study of neuroendocrine and meta-
bolic factors in HD, we designed a protocol to analyze
melatonin circadian rhythms in detail in cohorts of pre-
manifest and moderate HD subjects and controls.
Subjects and Methods
Fourteen premanifest HD gene carriers, 13 stage II/III
HD patients, and 15 control subjects were enrolled.
Patients were excluded if they had preexistent endocrine
disease, central nervous system disorder other than HD,
history of alcohol or drug abuse, treatment with corti-
costeroids, phenothiazine antiemetics or antipsychotic
medication (including neuroleptics, selective serotonin
reuptake inhibitor drugs), or hypnotic drugs during the
preceding 6 months, or night shift working and recent
weight change in the preceding 6 months. The study
was approved by University College London/University
College London Hospital ethics committee.
Participants were admitted to a private clinical room,
intravenous cannula inserted, and clinical assessment
and HD rating scales (Unified Huntington’s Disease
Rating Scale [UHDRS] and total functional capacity
[TFC]11) performed. The subject could walk freely,
watch TV, but not fall asleep or snack outside sched-
uled times. At 10:00 PM, they retired to bed and lights
were turned off until 6:00 AM. Hourly blood samples
were taken over 24 hours, using a long line to minimize
sleep disruption. Melatonin samples were placed on ice
before centrifugation at 4oC at 175 g for 10 min.
Plasma was immediately placed on dry ice and stored at
280C, before analysis.
Plasma Analyses
Plasma melatonin was measured in duplicate by
radioimmunoassay (Labor Diagnostika Nord GmbH
& Co. KG, Nordhorn, Germany). Detection limit of
the assay was 3 pg/mL, with 3 to 1000 pg/mL range,
interassay variability of 9.6 to 16.2%, and 78.3%
recovery.
Statistical Analysis
Results are expressed as mean6 standard deviation
(SD) unless otherwise specified. Intergroup differences
were assessed by linear regression on disease group (in
three categories), age, and sex. Logarithms were taken
where this improved normality of residuals. Regres-
sion was conducted with and without outlying values,
and P-values were little changed by their exclusion.
Semi-partial correlation coefficients were calculated
between melatonin levels and disease burden/func-
tional capacity, adjusted for age and sex. All tests
were two-tailed. Analyses were performed using SPSS
for Windows (16.0, SPSS, Inc.,Chicago, IL).
Circadian variation of plasma melatonin was quanti-
fied by best-fit curve obtained using locally weighted
linear regression with Gaussian kernel with a regres-
sion window of 4 h.12 The following definitions were
used: Nadir and acrophase concentrations, minimum
and maximum of best-fitting curve; amplitude concen-
tration, half the difference between acrophase and
nadir values; onset of melatonin rise, time of first
plasma level exceeding mean 13 SDs of baseline val-
ues over the 11:00 AM to 3:00 PM period, not followed
by lower concentrations before acrophase; melatonin
offset, time of last value occurring after acrophase
exceeding 23 SDs of baseline levels12; nocturnal dura-
tion, length of time between melatonin onset and
offset.
Fourier Transformation (FT) analysis was used to
measure spectral power of melatonin oscillations, ena-
bling analysis of the strength/power of hormonal
TABLE 1. Demographic, clinical features and melatonin data for Control and HD cohorts expressed as mean (standard
deviation)
Stage Controls Premanifest HD Stage II/III HD pa
Number of subjects 15 14 13
Mean age (range) 52 (29-69) 45 (31-58) 55 (42-70)
Female:Male 6:9 9:5 5:8
Mean CAG (range) — 42 (40-47) 44 (42-47)
Mean burden score (range) — 300 (207-434) 435 (273-702)
UHDRS Total Functional Capacity — 13 (12-13) 8 (5-12)
UHDRS Motor Score — 2 (0-11) 38 (10-65)
Melatonin concentration (pg/mL):
Mean over 24 hours 89 (68) 52 (41) 37 (58) 0.007
Nadir 12.9 (10.4) 10.5 (10.8) 7.9 (10.7) 0.47
Acrophase 292 (245) 155 (121) 112 (189) 0.005
Amplitude 140 (121) 72 (57) 52 (91) 0.004
Onset time (hh:mm) 22:34 (01:17) 22:47 (02:47) 22:37 (03:26) 0.96
Offset time (hh:mm) 07:04 (02:01) 07:04 (01.37) 08:00 (04:27) 0.97
Nocturnal duration (h) 8.5 (2.5) 8.3 (3.5) 7.5 (4.8) 0.74
aP-values for differences between means, adjusted for age and sex.
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oscillations at different frequencies.13 Signal–noise
ratio was improved by using a 3-point moving aver-
age, and any trend in the data was removed by a dif-
ference1mean regression. Data were analyzed by
using the EASY-TSA program14 (Oxford University,
UK: Nathan.hill@phc.ox.ac.uk). Comparisons between
waveforms of time series analysis were performed by
probability of standard error of mean (SEM) at any
discrete time point, overlapping the SEM of the com-
parative group.
Results
Table 1 shows demographic and clinical data for the
cohorts. Analysis of mean plasma melatonin concen-
trations for the three groups over 24 hours indicates
reduced nocturnal concentrations, acrophase, and
amplitude concentrations in premanifest and affected
subjects (Table 1, Fig. 1A, 1B). P values in Table 1
reflect a joint test of differences between all three
groups (after adjustment for age and sex).
Adjusted for age and sex, mean 24-hour melatonin
concentrations in Stage II/III HD are 82% lower (95%
confidence interval, 49-94% lower, P50.002) than
controls, and 68% lower (90% lower to 2% higher,
P5 0.053) than pre-manifest disease (results are
obtained in percentage terms, because logs were taken
before analysis). Acrophase concentrations in Stage II/
III HD are 86% lower (56-95% lower, P5 0.001)
than controls, and 71% lower (2-92% lower,
P5 0.047) than pre-manifest disease. Amplitudes in
Stage II/III HD are 87% lower (59-96% lower,
P5 0.001) than controls, and 75% lower (9-93%
lower, P5 0.04) than pre-manifest disease. Mean,
acrophase, and amplitude concentrations for pre-
manifest HD were lower compared with controls, but
did not reach significance.
No significant differences were seen in melatonin
secretion onset, offset, or duration of nocturnal secre-
tion (Fig. 1C, Table 1). However, whereas in most
control subjects, melatonin onset occurred between
9:00 PM and midnight, in HD gene carriers, the mela-
tonin onset was more temporally spread (P5 0.006
and P5 0.001 for pre-manifest HD and moderate
HD, respectively, each compared with controls, by
variance ratio test). Fourier transformation (FT) analy-
sis (Fig. 1D) showed a dominant pulsatility at 132
min for all groups (control, 7.5, SEM, 3.0%; pre-
manifest, 3.8, SEM, 1.6%; Moderate, 2.1, SEM,
1.0%) with minor repetition of periodicity at 660
minutes. The strength of spectral power at 132
minutes was lower in the stage II/III and pre-manifest
FIG. 1. Analysis of melatonin in control, pre-manifest, and stage II/III
HD cohorts. (A) Mean melatonin concentrations over 24-h sampling
period in the three groups. The black bar on the abscissa indicates
the dark period (10:00 PM26:00 AM). (B) Box plot showing distributions
of acrophase concentrations in healthy controls, pre-manifest, and
Stage II/III subjects. The bars with bold stars indicate statistical signifi-
cance (*P 0.05, ***P 0.001). (C) Box plot showing distribution of
melatonin onset time in the three groups. (D) FT analysis of melatonin,
plotting strength/power (%) against frequency (minutes) of melatonin
oscillations for the three groups. Circle and stars in B and C represent
outlying values.
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groups in comparison with controls. Pairwise compari-
son showed significance between the stage II/III and
control groups (P< 0.03), but the overall between-
group comparison did not reach statistical significance.
We did not find evidence of associations between
the melatonin variables investigated in Table 1 and
UHDRS motor score, TFC, CAG repeat, or repeat
burden score15 when corrected for age, sex, and multi-
ple comparisons.
Discussion
This is the first study to demonstrate that plasma
melatonin concentrations are reduced in subjects with
HD, suggesting that melatonin secretion is disrupted.
Our data also show that melatonin acrophase concen-
trations and amplitude of secretion are reduced. Mela-
tonin secretion declined with disease progression, with
lower concentrations and a trend for reduced pulsatil-
ity of secretion in the stage II/III patients compared
with controls. The study also found lower melatonin
concentrations in premanifest HD, although this did
not reach significance but showed a temporal spread
of onset of melatonin nocturnal rise in both premani-
fest and stage II/III HD subjects. We corrected for age
and sex, because the pre-manifest cohort was not as
closely matched to the pre-manifest group as the stage
II/III. Sampling hourly throughout the night could rep-
resent a source of error, but individual and best-fit
plots for controls show a typical melatonin increase
overnight, suggesting no disruption of nocturnal
secretion.
A previous study of a single time point measurement
of melatonin (in the morning after an overnight fast)
in advanced HD patients did not detect a difference
compared with controls.16 Our data show that single
measures cannot reflect the dynamic range of melato-
nin over 24 hours. Additionally, in Figure 1A, early
morning melatonin levels are similar in all three
groups, which may explain this negative finding.
Indeed, between 8:00 AM and 1:00 PM, the melatonin
concentrations in controls, pre-manifest HD, and stage
II/III HD subjects are similar, suggesting that meas-
uring melatonin during this period is unlikely to show
a difference.
Aziz et al.10 studied a small group (n59) of early
stage HD subjects and controls and found no differ-
ence in melatonin concentration, but correlated diur-
nal melatonin levels with motor score and TFC,10
suggesting an effect of HD on melatonin concentra-
tions not detectable in their small cohorts. They also
identified an 80-minute delay in evening rise of mela-
tonin. Although we also observed a delay in evening
melatonin rise in some HD gene carriers, we also
noted a similar number of HD subjects with an
advanced melatonin rise; therefore, we conclude that
the rise of melatonin is temporally altered. We showed
a decrease in melatonin concentrations from control
to pre-manifest and moderate HD, but no correlation
with clinical indicators of disease severity (UHDRS
motor score, TFC) and CAG repeat burden, possibly
reflecting that melatonin is a specific marker for SCN/
pineal function. The larger patient groups and inclu-
sion of subjects with more advanced HD (stage II/III)
may explain why lower melatonin concentrations
were found in our study.
The SCN keeps local circadian clocks synchronized
with both each other and the solar cycle.17 Disrupted
and reduced melatonin secretion may indicate dysfunc-
tion or degeneration of SCN neurons, with abnormal
circadian rhythm and integration of light/dark cycle. A
study of knock-in transgenic mice with a 175 CAG
repeat identified both gene dosage and age-dependent
circadian disruption, although histological analysis of
the SCN did not identify cell loss.18 However, a study
in human HD post-mortem tissue found evidence of
post-transcriptional changes in SCN neuropeptides,
suggesting a functional abnormality.19 This may play
a role in the melatonin changes we found and sleep
abnormalities in HD. Restoring nocturnal melatonin
levels may prove therapeutic, and a trial of melatonin
for HD sleep disturbance is warranted. Melatonin
may also be neuroprotective and can delay disease
onset and mortality in R 6/2 mice.20
The precise cause of the sleep abnormalities in HD
is not known and may involve complex interplay
between the hypothalamus, basal ganglia, cortex, and
brain stem.17 Recent studies in the R 6/2 mouse identi-
fied significant circadian behavior, sleep, and electro-
encephalogram disturbance in the transgenic mice,
detectable at even a presymptomatic stage.21,22 How-
ever, neuroendocrine factors were not analyzed in
these studies.
Sleep disorders are seen in other neurodegenerative
disorders, including Parkinson’s disease (PD), and since
submission of this paper two reports of reduced mela-
tonin levels in PD subjects have been published, also
suggesting a link with sleep disorders.23,24 Thus, disrup-
tion of melatonin synthesis and release may be seen
more widely in neurodegeneration, although involve-
ment of the SCN in PD pathology is not known.
Our data demonstrate for the first time a significant
abnormality in melatonin concentrations in HD
patients, offering therapeutic strategies and potential
as state biomarker to track disease progression in HD.
A biomarker for disease trait is not needed for HD,
because it can be clearly differentiated from other neu-
rodegenerative disorders with the CAG repeat genetic
test.
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